CONTACT US   |  (864) 397-5101

Sharps Technology Provides Update on Commercialization Activities, is Highlighted in Med Tech Outlook Article

nephron and sharps

Company advances commercialization of Securegard smart safety syringe line through qualification programs with major med device company

Production of prefilled syringe products will begin in Q4 of 2023 to support the co-manufacturing agreement with Nephron Pharmaceuticals

NEW YORK, July 06, 2023 (GLOBE NEWSWIRE) — Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, announces an update on commercialization activities and is highlighted in Med Tech Outlook feature article.

Med Tech Outlook named Sharps Technology, Inc. the “Top Safety Syringe Manufacturer in 2023” and featured the Company in a cover article in the July edition of the publication, which can be found HERE. The article, entitled “Sharps Technology, Inc.: Modernizing Drug Delivery with Novel Safety Syringe System Innovations”, reviews the Company’s technology offerings, transformative partnership with Nephron Pharmaceuticals, its next generation polymer-based prefillable syringe systems, and strategy forward with commercialization. Sharps was privately founded in 2017 with a vision to develop innovative drug delivery technology, and the Company is now advancing its products from research and development to commercial sales that are expected to launch in 2023.

Sharps has entered into an agreement with a major medical device company that will begin the qualification process for its smart safety syringe technology to help drive commercial revenue in 2023. The agreement will begin with 1ml and 3ml Securegard product line and will be followed by Sologard® vial-draw products for larger volume drug applications. The Company’s Securegard smart safety syringe platform will benefit healthcare workers through a combination of active safety systems, providing ultra-low waste technology with re-use prevention, and the ability to reduce medical container waste. The agreement will allow for the opportunity to create secondary sales agreements with additional key hospital networks as part of the qualification work. 

In preparation for the commercialization of the Company’s next-generation polymer-based prefilled syringe systems, Sharps will begin production of the introductory products in the fourth quarter of 2023. This work will be the first efforts to support the co-manufacturing agreement between Sharps and Nephron at the prefilled syringe Inject-EZ operation in Columbia, South Carolina. Products will include 10ml and 50ml configurations designed to support the 503B programs at Nephron as well as the demand from other drug fill-finish companies.  The 10ml and 50ml products have specific features and advantages that will benefit these pharmaceutical filling companies that produce products in support of the drug shortage programs defined by the FDA and U.S. government.

“As we advance our commercialization strategy for Sharps’ specialty syringe systems, we are at a pivotal time in the Company’s history,” commented Robert Hayes, Sharps Technology CEO. “We are committed to launching our line of Securegard products and commencing the manufacturing of next-generation polymer-based prefilled systems in 2023, which will transform the Company. The qualification process is underway for Securegard at a large medical device company, and we look forward to providing updates as the product advances through the confirmation process. Sharps’ specialty polymer-based prefilled products will be manufactured in the U.S. at Nephron’s facility in Columbia, South Carolina. It is a significant milestone for Sharps to have the ability to have manufacturing capacity in the U.S. that will produce prefilled syringes to support both the healthcare industry and the Company’s growth.”

About Sharps Technology

Sharps Technology is a medical device and pharmaceutical packaging company specializing in the development and manufacturing of innovative drug delivery systems. The Company’s product lines focus on low waste and ultra-low waste syringe technologies that incorporate both passive and active safety features. These features protect front line healthcare workers from life-threatening needle stick injuries and protect the public from needle re-use. Sharps Technology has extensive expertise in specialized prefilled syringe systems and ready to use processing. The Company has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand its manufacturing capacity in the U.S. For additional information, please visit www.sharpstechnology.com.

Join now to enjoy expanded member benefits!

Enjoy exclusive member content, special events, savings, networking and more

Tamia Sumpter

Tamia is a driven senior undergraduate Bioengineering student currently enrolled at Clemson University. With a strong foundation in her field, she has honed her skills through hands-on experience in research and development at Eli Lilly & Company. During her time in the ADME department, Tamia contributed significantly by working on siRNAs and their applications in finding In Vitro-In Vivo Correlation (IVIVC). Looking ahead, Tamia has set her sights on a promising career in law. She aspires to specialize in Intellectual Property Law, with a particular focus on serving as in-house counsel for leading medical device or pharmaceutical companies. Her enthusiasm for this role is palpable as she prepares to embark on her legal journey! She is also a proud member of the Omicron Phi chapter of Delta Sigma Theta Sorority, Inc., PEER Mentor for Clemson PEER/WiSE, and currently serves as the President of Clemson Bioengineering Organization (CBO). With her unique blend of scientific knowledge and legal interests, Tamia is poised to make a meaningful impact in the healthcare and life sciences industries.